← All trials

NCT07023302

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jun 19, 2025
Primary completion
Feb 28, 2029
Completion date
Feb 28, 2029
First posted
Jun 16, 2025
Last posted
Aug 26, 2025
Enrollment
123
Arms / groups
10 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.